Clonal blood mutations common in breast cancer may sharply raise heart failure risk after anthracyclines, urging better screening and personalized cardio-oncology care.
Hanna Jensen
Advertisement
Articles by Hanna Jensen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
3
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
4
Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3
5